The professional and research oncology community has done a poor job of serving patients when it comes to providing quality information about alternative and complementary, or integrative approaches to cancer care. Even in areas that are now becoming more accepted by patients and physicians, such as the use of psychological and nutritional support, very little data have been generated that are really useful to patients. Mega-dose vitamin supplementation is a commonly sought approach in cancer care, and this is based in part on extrapolations of the activity of vitamin cofactors in disease and health as well as laboratory data that support both direct anticancer effects and effects on the immune function. However, clinical effects of vitamins, minerals, and antioxidant supplementation (hereafter referred to in aggregate as supplementation therapy) in early stage breast cancer have never been studied in a controlled randomized trial, despite the common use and interest in this setting. 1 Hence, most medical oncologists have been reluctant to make any recommendations in this area and even tend to advise against the use of such supplements out of concern that it may interfere with the activity of conventional hormonal and chemotherapeutic drugs. On the other hand, supplementation therapy remains of great interest to patients and is also embraced by many naturopathic and holistic physicians and care providers.
It is clear that laboratory and other preclinical models of cancer are not very predictive of clinical effects. The genetic and cellular complexities, the individual diversity seen across human tumors of the same type, and the intricacies of tumor host interaction dictate that clinical trials must ultimately confirm laboratorybased hypotheses. Oftentimes, clinical effects are overestimated. Nevertheless, clinical trials involve some human risk and thus a high priority must be given to those trials that have a physiological basis or a strong clinical experience to support the experimental arm. Supplementation therapy meets both these criteria with some laboratory data suggesting an effect from vitamins and antioxidants, 2 as well from small patient case series, 3, 4 case-control studies showing lower risk of breast cancer, 5 and large cohort studies suggesting lower risk of breast cancer with vitamin A supplementation, especially if the diet is vitamin Adeficient. 6 However, in the breast cancer preventive setting, most other vitamin and micronutrient cohort studies or even randomized trials have failed to show a significant effect. 7 Many investigators in the burgeoning field of integrative medical research rely on evidence from the laboratory as well as cohort or case-control studies prior to proposing a large-scale randomized trial just as would be the case in any other field. This is necessary to assume that there is a basis for a positive clinical effect, that the modality is relatively safe and feasible, and to estimate a magnitude of the effect size to determine the appropriate sample size. However, in the field of integrative medicine, the modalities are often complex rather than "single agent" and are often individualized. Case series or cohort studies provide some information about safety and feasibility of specific approaches but are often criticized because of patient selectivity, which make outcome very difficult to interpret in a heterogeneous disease such as breast cancer. Case-control studies, in which patients are matched for characteristics that are known to influence outcome, can correct for some of these biases, but the problem of unanticipated biases still is problematic. This is especially true for lifestyle studies since many factors such as the use of alcohol and tobacco can be linked to other factors such as motivation and likelihood to seek medical care at an early juncture.
The study by Lesperance and colleagues at the British Columbia Cancer Agency (BCCA) stands out as a noteworthy example of the power of a well-designed case-control study. Supplementation therapy was assessed using a reasonably uniformly prescribed regimen of beta-carotene, vitamin C, selenium, niacin, coenzyme Q 10 , and zinc. All supplementation treatment was rendered at one center by one physician (not affiliated with the BCCA). The BCCA maintains a cancer registry with excellent follow-up and consistently applied treatment guidelines such that this agency has contributed significantly to the breast cancer literature. The extensive database from all patients seen at the BCCA-Vancouver Cancer Centre allowed the investigators to perform a sophisticated 2:1 matched control set that was adjusted for age, tumor size, nodal status, grade, estrogen receptor, year of diagnosis, type of treatment, and even the presence of lymphatic or vascular invasion. The resulting level of matching was much better than is typical for such studies. Furthermore, the matched controls were population-based rather than clinic-based, and hence were more likely to be representative of the general breast cancer population.
The relapse-free and overall survival rates were not statistically different in the supplementation therapy compared with control; in fact, there was a trend for a worse outcome with supplementation. Despite the excellent study plan and matching procedure, there was an imbalance in the number of patients who received breast-conserving surgery without radiation in the supplementation group. This may have increased the number of recurrences in this group, although the effect of radiation on distant recurrences is felt to be very small. However, this points out the weaknesses of even a meticulous case-control studythat is, the problem of unforeseen biases. For example, it is possible that the type of individual who would seek supplementation therapy may also be reluctant to undergo radiation therapy. Although this assumption is only speculative, it illustrates the inherent limitations of any study that is not a large randomized trial. One simply cannot match for every possible association that may be different among cases and controls in such a study, yet some associations may influence the outcome. When the case population is highly selected, this increases the chance of this type of bias. The cases were all from one clinical practice, and then even more were selected to include patients who were diagnosed after 1989 (this is when the BCCA began keeping detailed data) and who took supplementation for at least 2 months beginning within 180 days of diagnosis of breast cancer. This resulted in a subset of only one third of the original patients with breast cancer seen at the center that provides supplementation therapy.
Another common problem with such studies is the limited statistical power. The authors hypothesized that supplementation therapy might improve breast cancer-specific and disease-free survival by 25% to 30%. However, this is a very optimistic estimate-hormonal and chemotherapy yield effects of about this size, or even smaller. 8, 9 Even with this rather generous assumption, 271 supplementation therapy patients would have been required, but only 90 were included after the requisite selection criteria. With this lower-than-expected number of patients, the resulting increase in survival that could have been detected with a reasonable power would have been even greater than 25% to 30%, although this figure was not actually calculated and provided in the article. If one were to perform a trial or retrospective analysis that would usefully address this issue, one must ask what reduction in recurrence risk would justify supplementation therapy. Since supplementation therapy is rather safe and inexpensive, even a small reduction in risk, such as a relative reduction of 10% to 20% (which might translate into an absolute reduction of only 1% to 10% depending on the risk features of the individual's primary tumor) would be worthwhile. The best design, of course, would be a prospective randomized controlled trial using the same regimen (or a set of regimens depending on the patient's risk). This would require a sample size of several thousand patients, which is now the typical size of randomized trials involving patients with early stage breast cancer.
Since many other forms of complementary medicine, even those that are rather mainstream, fall into this general conundrum, what are the prospects for the future? Although much of medical practice is applied without high levels of evidence based on prospective controlled randomized trials, there has clearly been a trend toward addressing common illnesses with large studies and even developing cost/ benefit analyses and practice guidelines. The pharmaceutical industry has also aggressively performed trials to maximize their chances for gaining FDA approval on patentable drugs and to increase their market share. There is less funding available for modalities not associated with intellectual property, such as exercise, nutrition, and mind body approaches. Even though many of these approaches can be highly costeffective, especially when used in the preventive setting, studies in this area are poorly represented in the overall portfolio of industry-sponsored cancer clinical trials. The principal funding agencies that support these studies are the National Institutes of Health and, to a lesser degree, nonprofit agencies such as the American Cancer Society. These cumulative expenditures pale compared with the amount available from the private sector. Supplementation therapy is still regarded as complementary or alternative medicine, and thus falls into a category that is even more underfunded. It was by congressional mandate that the NIH set up the Office of Alternative Medicine and later insisted on its elevation to the National Center for Complementary and Alternative Medicine (NCCAM) with its own budget and discretionary power to issue requests for applications and other priorities for funding. The NCCAM has a very limited budget compared with the other institutes, although one could argue that a well-conceived supplementation therapy trial could be done outside the NCCAM through the current cooperative cancer group mechanism.
Will there ever be a definitive trial of supplementation therapy for early stage breast cancer? Should there be? Certainly the public and advocacy interest in this area and the high prevalence of the practice of supplementation warrants that we seek an answer. However, it is unlikely that the oncology community or the NIH at this point would support a definitive large randomized trial to assess the benefits of supplementation therapy in early stage or advanced stage breast cancer. A pilot randomized trial would not have sufficient statistical power to measure anything but a large difference in safety or efficacy. Case-control studies such as this one, even when designed and executed in an excellent fashion, are complicated by numerous hidden biases despite extensive matching. This is primarily due to the fact that many integrative approaches are sought by patients whose lifestyles, habits, and preferences for medical care are different from the control populations. This is the typical catch-22 that bedevils clinical research in complementary or integrative medicine. Although it is best to follow the algorithm of a pilot trial followed by a definitive randomized trial, it may be necessary to converge on a single supplementation program for which there is a high level of agreement among practitioners as well as demonstrated safety and feasibility, and then take this straight to a randomized large-scale multicenter study. The medical oncology community will need to be surveyed to see if such a trial will be supported. More general survey studies in the past have suggested that both patients and physicians are open to cancer trials involving complementary medicine. 10 Finally, the randomization process would need to be palatable to patients-especially those who would be interested in integrative medicine. Patients frequently cite concern about randomization as a principal barrier to trial participation. 10 It will ultimately be up to the community of integrative medicine clinical investigators to move this agenda forward and bring the remainder of the oncology discipline on board with the help of advocates and governmental funding agencies. Only through this process can we really get the answers about supplementation therapy that the public deserves.
